Markets:

Overview

News

Currencies

International

Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

92.67 +1.88 (+2.07%)

Streaming Delayed Price Updated: 10:16 AM EDT, Aug 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Celcuity (CELC) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

Revtopik launch underway with 80 oncology specialists supporting expansion into first-line treatment.

Via The Motley Fool

Topics Earnings

Celcuity Q2 Earnings Call Highlights ↗

August 13, 2026

Celcuity (NASDAQ:CELC) said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026...

Via MarketBeat

Topics Earnings

Celcuity Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 13, 2026

On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call...

Via Benzinga

Topics Earnings

Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer ↗

July 15, 2026

Celcuity (NASDAQ:CELC) said the U.S. Food and Drug Administration has granted full approval to gedatolisib, now branded as REVTORPYK, for certain patients with advanced breast cancer, marking the...

Via MarketBeat

Celcuity Inc. (NASDAQ:CELC) Q1 Earnings Beat Forecasts, But Stock Drops on Phase 3 Data Focus ↗

May 14, 2026

Via Chartmill

Topics Earnings

Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib ↗

March 25, 2026

Via Chartmill

Topics Earnings

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....

Via InvestorPlace

Stay updated with the stocks that are on the move in today's pre-market session. ↗

June 02, 2026

Via Chartmill

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗

May 30, 2026

Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.

Via The Motley Fool

Topics Regulatory Compliance

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗

May 17, 2026

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

Via The Motley Fool

Topics Regulatory Compliance

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗

May 17, 2026

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Via The Motley Fool

Celcuity Q1 Earnings Call Highlights ↗

May 14, 2026

Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its...

Via MarketBeat

Topics Earnings

Celcuity (CELC) Q1 2026 Earnings Transcript ↗

May 14, 2026

Celcuity (CELC) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗

May 10, 2026

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗

May 10, 2026

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.

Via The Motley Fool

Traders are paying attention to the gapping stocks in Monday's session. ↗

May 04, 2026

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

May 04, 2026

Via Chartmill

Why Celcuity Stock Popped on Monday ↗

April 27, 2026

An analyst initiated coverage of the biotech.

Via The Motley Fool

Why Celcuity Stock Popped Today ↗

March 26, 2026

The cancer-focused biotech published its final set of figures for 2025.

Via The Motley Fool

The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026

March 24, 2026

As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗

March 20, 2026

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

Via The Motley Fool

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Via The Motley Fool

Topics Regulatory Compliance

Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing ↗

March 10, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Closes Position in GEO Stock, Sells $17.6 Million Worth of Shares, According to Recent SEC Filing ↗

March 10, 2026

This corrections firm delivers facility management and reentry services to government clients in the U.S., Australia, and South Africa.

Via The Motley Fool

Topics Immigration Regulatory Compliance

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗

March 09, 2026

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗

March 06, 2026

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

The Great Rotation of 2026: Why Small-Cap 'Underdogs' are Finally Outpacing the Tech Titans

March 04, 2026

The first quarter of 2026 has ushered in a dramatic reversal of the decade-long market hierarchy. After years of trailing in the shadow of mega-cap technology giants, small-cap stocks—the perennial...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.